Case report Interferon-c for delayed pulmonary toxicity syndrome resistant to steroids

Summary: Delayed pulmonary toxicity syndrome, characterized by interstitial pneumonia and pulmonary fibrosis, is common following high-dose bischloroethylnitrosourea (BCNU) (carmustine, [1,3-bis (2-chloroethyl)-1-nitrosourea]) containing chemotherapeutic regimens. Depending upon the treatment protocol, it may develop in over 70% of patients. Early and aggressive corticosteroid treatment leads to improvement in the majority of patients. However, up to 8% of affected patients may fail to respond to corticosteroids and develop progressive respiratory failure leading to death. No alternatives to corticosteroids have thus far been shown useful. We report the symptomatic and physiological improvement of a patient with severe steroid-resistant delayed pulmonary toxicity syndrome, following treatment with interferon-c. Bone Marrow Transplantation (2003) 31, 939–941.

[1]  G. Broadwater,et al.  Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  R. Negrin,et al.  Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  W. Petros,et al.  Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. , 2000, American journal of respiratory and critical care medicine.

[4]  V. Petkov,et al.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. , 1999, The New England journal of medicine.

[5]  J. Erasmus,et al.  Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. , 1998, American journal of respiratory and critical care medicine.

[6]  L. Norton,et al.  Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment , 1997, Bone Marrow Transplantation.

[7]  B. Overmoyer,et al.  High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodes , 1997, Bone Marrow Transplantation.

[8]  M. Anscher,et al.  Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity. , 1995, Bone marrow transplantation.

[9]  L. Tuason,et al.  Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). , 1995, Chest.

[10]  E. Patz,et al.  Pulmonary Drug Toxicity Following High‐Dose Chemotherapy with Autologous Bone Marrow Transplantation: CT Findings in 20 Cases , 1994, Journal of thoracic imaging.

[11]  M. Anscher,et al.  Transforming Growth Factor β as a Predictor of Liver and Lung Fibrosis after Autologous Bone Marrow Transplantation for Advanced Breast Cancer , 1993 .

[12]  G. Rosner,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Piantadosi,et al.  Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. , 1993, The American review of respiratory disease.

[14]  E. Shpall,et al.  Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. , 1993, Journal of the National Cancer Institute.

[15]  G. Raghu,et al.  Effect of γ-Interferon on Collagen Synthesis by Normal and Fibrotic Human Lung Fibroblasts , 1992 .

[16]  L. Koss,et al.  BCNU (1,3‐Bis‐(2‐chloroethyl)‐1‐nitrosurea) lung. Drug‐induced pulmonary changes , 1984, Cancer.

[17]  S. Rudnick,et al.  Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. , 1980, The New England journal of medicine.

[18]  A. Bartolucci,et al.  Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). , 1979, Annals of internal medicine.